Etoposide and doxorubicin antagonize the in vitro activity of paclitaxel in human non-small cell lung cancer cell lines

Lung Cancer

Volumn 15, Issue 1, 1996, Pages 93-101

  Viallet, J ^a,b   Tsao, M S ^c   Gallant, G ^d  

^a NOTRE DAME HOSPITAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c MONTREAL GENERAL HOSPITAL   (Canada)

^d BRISTOL MYERS SQUIBB   (United States)

Author keywords

Cell lines; Drug antagonism; In vitro drug testing; Non small cell lung cancer; Paclitaxel

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CISPLATIN; DOXORUBICIN; ETOPOSIDE; PACLITAXEL; VINBLASTINE;

ARTICLE; CANCER CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ANTAGONISM; DRUG POTENTIATION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL;

EID: 0030220287     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/0169-5002(96)00574-0     Document Type: Article

References (14)

1. [1] Boyd MR, Shoemaker RH, McLemore TL et al. New drug development. In: Roth JA, Ruckdeschel JC, Weisenburger TH, editors. Thoracic oncology. Philadelphia, PA: Saunders, 1989; 711-721.
2. [2] Cabral F, Wible L, Brenner S et al. Taxol-requiring mutant of Chinese hamster ovary cells with impaired mitotic spindle assembly. J Cell Biol 1983; 97: 30-39.
3. [3] Carmichael J, Mitchell JB, DeGraff WG et al. Chemosensitivity testing of human lung cancer cell lines using the MTT assay. Br J Cancer 1988; 57: 540-547.
4. [4] Giaccone G. New drugs in non-small cell lung cancer. An overview. Lung Cancer 1995; 12 Suppl 1: S155-S162.
5. [5] Hahn SM, Liebmann JE, Cook J et al. Taxol in combination with doxorubicin or etoposide. Possible antagonism in vitro. Cancer 1993; 72: 2705-2711.
6. [6] Ihde DC and Minna JD. Non-small cell lung cancer. Pan II: Treatment. Curr Probl Cancer 1991; 15: 105-154.
7. [7] Jekunen AP, Christen RD, Shalinsky DR et al. Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro. Br J Cancer 1994; 69: 299-306.
8. [8] Langer CJ, Leighton JC, Comis RL et al. Paclitaxel and carboplatin in combination in the treatment of advanced non-small cell lung cancer: a phase II toxicity, response, and survival analysis. J Clin Oncol 1995; 13: 1860-1870.
9. [9] Schmid SM, Garrett BD, Coffield RT, et al. Combination interferon beta/taxol in vitro with cell lines of various histogenesis: supra-additive effects. Proc Am Assoc Cancer Res 1992; 33: 443.
10. [10] Steel GG and Peckham MJ. Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys 1979; 5: 85-91.
11. [11] Tishler RB, Schiff PB, Geard CR et al. Taxol: a novel radiation sensitizer. Int. J. Radiat Oncol Biol Phys 1992; 22: 613-617.
12. [12] Tsai C-M, Gazdar AF, Venzon DJ et al. Lack of in vitro synergy between etoposide and cis-diammine-dichloroplatinum (II). Cancer Res 1989; 49: 2390-2397.
13. [13] Vafai D, Israel V, Zaretsky S et al. Phase I/II trial of combination carboplatin and taxol in non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1995; 14: 352 ( # 1067).
14. [14] Weisenthal LM. Antineoplastic drug screening belongs in the laboratory, not the clinic. J Natl Cancer Inst 1992; 84: 466-469.